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Abstract: Recent evidence suggests that autophagy impairment is implicated in the epileptogenic
mechanisms downstream of mTOR hyperactivation. This holds true for a variety of genetic and
acquired epileptic syndromes besides malformations of cortical development which are classically
known as mTORopathies. Autophagy suppression is sufficient to induce epilepsy in experimental
models, while rescuing autophagy prevents epileptogenesis, improves behavioral alterations, and
provides neuroprotection in seizure-induced neuronal damage. The implication of autophagy in
epileptogenesis and maturation phenomena related to seizure activity is supported by evidence
indicating that autophagy is involved in the molecular mechanisms which are implicated in epilepsy.
In general, mTOR-dependent autophagy regulates the proliferation and migration of inter-/neuronal
cortical progenitors, synapse development, vesicular release, synaptic plasticity, and importantly,
synaptic clustering of GABAA receptors and subsequent excitatory/inhibitory balance in the brain.
Similar to autophagy, the ubiquitin–proteasome system is regulated downstream of mTOR, and
it is implicated in epileptogenesis. Thus, mTOR-dependent cell-clearing systems are now taking
center stage in the field of epilepsy. In the present review, we discuss such evidence in a variety of
seizure-related disorders and models. This is expected to provide a deeper insight into the molecular
mechanisms underlying seizure activity.
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1. Introduction
Seizures are produced by abnormal, synchronous, high-frequency neuronal firing within the
central nervous system [1]. Epilepsy is a chronic neurological disorder featuring recurrent, unprovoked
seizures. The term epilepsy actually comprises a number of aetiologically diverse syndromes, which are
associated with either inborn or acquired brain malformations, structural lesions, or other neurological
disorders [2]. During epileptogenesis, that is, the process of converting a nonepileptic brain into one
capable of generating spontaneous, recurrent seizures, a plethora of structural and cellular mechanisms
occur, fostering persistently increased neuronal excitability and abnormal plasticity [3,4]. Neuronal
hyperexcitability is mainly attributed to an imbalance between glutamate and gamma-aminobutyric
acid (GABA) neurotransmitter systems, though alterations in catecholamine systems play a role in
epileptogenesis as well [5].
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Among the intracellular signaling pathways implicated in epileptogenesis, the mammalian target
of rapamycin (mTOR) has received particular attention due to its multiple roles in brain development,
neuronal excitability, and plasticity, as well as inflammation and immunity [6,7]. The key role of the
mTOR pathway in epileptogenesis is best exemplified by tuberous sclerosis complex (TSC) and focal
cortical dysplasia (FCD), the most common genetic causes of epilepsy [8]. As extensively documented in
the literature, mTOR hyperactivation due to mutations in phosphatase and tensin homolog (PTEN) and
TSC1/2 genes leads to epileptogenesis in human samples and mouse models; conversely, inhibition of
mTOR prevents the development of epilepsy and underlying neuronal alterations [9–14]. Accumulating
evidence indicates that mTOR also participates in epileptogenesis associated with other forms of
genetic or acquired epilepsy such as Lafora disease (LD), temporal lobe epilepsy (TLE), traumatic
brain injury, and experimental epilepsy induced by chemoconvulsive compounds [11–14]. As recently
addressed, mTOR pathway activation is also implicated in autoimmune diseases such as systemic lupus
erythematosus (SLE), which represents a prominent cause of seizures [7]. Clinical cases of fulminant
SLE have also been documented in TSC patients, supporting a key role of mTOR in seizure development
associated with these disorders [15,16]. In detail, in SLE, mTOR acts as a critical driver of inflammatory
lineage development of the immune system while fostering generation of antiphospholipid antibodies,
which are mediators of seizure in adults and children alike [17,18].
An emerging mTOR-dependent mechanism contributing to epileptogenesis is bound to alterations
of cell-clearing systems. This emerged mainly from evidence indicating that rapamycin, a powerful
mTOR inhibitor and autophagy inducer, strongly modulates a variety of seizure models and
epilepsies [12,13]. More recently, direct evidence has been provided indicating a solid correlation among
mTOR-dependent autophagy, epileptogenesis and epilepsy-induced neuronal damage. In fact, similarly
to autophagy suppression which occurs following mTOR hyperactivation, impaired autophagy due to
the deficiency of ATG18 is linked to encephalopathic seizures [19,20], and ablation of ATG7 in mice
models leads to spontaneous seizures [21]. These findings suggest that autophagy failure may be
sufficient per se to induce epilepsy. In support of the role of autophagy disruption in the pathogenesis
of epilepsy, autophagy alterations are detected in human samples and experimental models of
epilepsy [21,22]. This casts the hypothesis that altered autophagy may contribute to the occurrence of
epilepsy, and in turn, that epilepsy could impinge on the autophagy pathway, creating a vicious cycle
which might further exacerbate epilepsy-induced neuronal damage. This would not be surprising
since autophagy regulates a variety of cell functions that are implicated in neurodevelopmental and
neurological disorders, including epilepsy. In fact, besides coping with harmful events such as oxidative
damage and mitochondrial alterations, mTOR-dependent autophagy regulates the proliferation and
migration of inter-/neuronal cortical progenitors, synapse development, axon guidance, dendritic
spine architecture and pruning, vesicular release, and synaptic plasticity [23–25]. Once thought
to play a merely housekeeping role by removing misfolded proteins or compromised organelles,
neuronal autophagy is now regarded as a finely tuned surveillance system, which operates in neurons
to guarantee synaptic integrity and function. This occurs, for instance, through degradation and
turnover of both pre- and post-synaptic substrates, including synaptic vesicles, scaffold proteins, and
neurotransmitter receptors [23–25]. In keeping with this, failure of mTOR-dependent autophagy
was recently shown to promote aberrant synaptic clustering of GABAA receptors and subsequent
imbalance of excitation–inhibition in the brain, which might be key for epileptogenesis [26]. Alterations
in mTOR-dependent autophagy are also implicated in abnormal dopamine system activity, which is
implicated in epileptogenesis as well [27]. In this context, synaptic plasticity, besides being modulated
by classic CNS molecules, is strongly affected by the immune system, and vice versa. This is due to a
bidirectional communication and common molecular pathways that operate at the crossroad between
the nervous and immune systems [28]. This is also the case for mTOR-related cell-clearing systems,
which handle lymphocytes’ and other immune cells’ metabolism as well as antigen processing within
both peripheral and CNS-resident antigen-presenting cells (APCs) [28]. Alterations in mTOR-related
cell-clearing systems may lead to defective or inappropriate communication between the immune
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and nervous system, giving rise to a chain of inflammatory/immune and synaptic alterations, which
may contribute to neurodevelopmental, neurological, and autoimmune diseases associated with
seizures [28]. As support to these findings, increasing evidence indicates that beyond rapamycin,
a variety of compounds that are known to induce autophagy may offer beneficial effects in epilepsy,
including that associated with autoimmune disorders such as SLE [29–33].
Still in this context, it is worth mentioning that beyond autophagy, the ubiquitin–proteasome system
(UPS), which regulates neuron excitability, synaptic plasticity, and neuro-inflammation/immunity, is
altered in epilepsy as well [34–37]. It is remarkable that, similar to autophagy failure, UPS alterations
in epilepsy are bound to mTOR hyperactivation [37]. This is in line with recent evidence documenting
the role of mTOR in modulating both cell-clearing systems and the morphological convergence
of autophagy and UPS [38–40]. In the present manuscript, we provide an update on the role of
mTOR in epileptogenesis while discussing possible biochemical and molecular mechanisms bridging
alterations of cell-clearing systems with epileptogenesis and epilepsy-induced neuronal alterations.
The findings discussed here suggest that mTOR-dependent autophagy and UPS play a key role in
epilepsy by producing plastic changes in the brain which may partially overlap with those responsible
for neuroprotection against excitotoxicity.
2. mTOR and Autophagy in Human and Experimental Epilepsy
2.1. The Emerging Role of mTOR-Dependent Autophagy in the Regulation of the GABAergic System
Deficits in the number, migration, and positioning of cortical GABAergic inhibitory interneurons
may lead to an imbalance of excitatory–inhibitory activity associated with overlapping neurological
and neurodevelopmental disorders including epilepsy and autism [41–43].
Recent studies unraveled a role for mTOR/autophagy in regulating interneuron progenitors in
the developing ventral telencephalon [44]. Conditional deletion of mTOR and subsequent autophagy
activation reduces the number of interneurons in the cerebral cortex. This occurs in the absence of
alterations of cortical interneurons’ positioning, suggesting a prominent role of mTOR-dependent
autophagy in progenitor self-renewal rather than migration [44]. Intriguingly, in developing neural
progenitors, a reciprocal regulation occurs between glycogen synthase kinase 3 (GSK3) and mTOR
activity, which is likely aimed at finely tuning interneuron proliferation and migration [45]. The inhibition
of GSK3 leads to elevation of mTOR activity, while overexpression of GSK3 suppresses mTOR activity. In
turn, mTOR inhibition suppresses the hyperproliferation of GSK3-deficient neural progenitors. However,
mTOR deletion per se does not produce any effects in radial migration of cortical projection neurons, at
least during early-stage migration. This, in turn, might be due to a predominant role of AKT/PI3K/GSK3
pathway compared with mTOR during early cortical neuron migration [45]. It is remarkable that both
mTOR and GSK3 are upstream negative regulators of autophagy, suggesting that autophagy is involved
in both mTOR- and GSK3-dependent modulation of cortical neuron development and migration.
This is supported by evidence indicating that autophagy failure is bound to alterations of Rac1
protein [46], which is negatively regulated by mTOR, and it is implicated in epileptogenesis through
regulation of interneuron migration. In detail, the deletion of Rac1 protein impairs the migration of
postmitotic interneurons, leading to the early onset of spontaneous epileptic seizures [47,48]. Rac1
deletion causes generalized hyperactivity and cognitive impairment due to higher excitability and
reduced spontaneous inhibitory currents in the Cornus Ammonis (CA) hippocampal pyramidal
neurons [48]. Intriguingly, in TSC2-deficient cells featuring mTOR hyperactivation, Rac1 accumulates
within cytoplasmic dots colocalizing with p62 and ubiquitin reminiscent of engulfed autophagy
vacuoles, suggesting an impaired autophagy flux. Conversely, rapamycin administration activates
Rac1 by dispersing its cytoplasmic aggregation [46]. Thus, autophagy activation rescues Rac1,
which indirectly suggests that autophagy induction may target epileptogenesis associated with
mTOR-dependent Rac1 dysfunction.
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In a similar fashion, autophagy suppression due to TSC2-related mTOR hyperactivation disrupts
the trafficking of GABAA receptors via the sequestration of γ-aminobutyric acid receptor-associated
proteins (GABARAPs) by p62-positive aggregates [26]. Such an effect is reproduced by autophagy
deficiency following either ATG7 or ULK2 deletion in forebrain inhibitory or excitatory neurons [26,49].
In fact, beyond LC3, proteins belonging to the GABARAP family have been shown to be involved in
the trafficking of GABAA receptors to the neuronal plasma membrane, and they also have numerous
binding partners that are involved in synapse formation, maintenance, and plasticity [23,50]. Following
autophagy failure, elevated p62 sequesters a higher proportion of GABARAP thus limiting the amount
of GABARAP available for GABAA receptor surface presentation, eventually leading to imbalanced
excitatory–inhibitory neurotransmission.
The present data indicate a novel physiological role for autophagy in regulating GABAergic signaling,
providing a potential mechanism for the reduced inhibitory inputs observed in neurodevelopmental and
neurological disorders such as epilepsy and autism [26]. These findings have bridged the gap between
mTOR, autophagy, and GABAergic signaling, which started to emerge in 2009 when the role of autophagy
in GABAA receptor trafficking was first demonstrated [51]. In summary, autophagy-dependent synaptic
clustering of GABAA receptors during synaptogenesis is important for the function of inhibitory synapses,
influencing synapse strength and, consequently, the balance of excitation and inhibition in the brain.
Importantly, autophagy is implicated in neurotransmitter release as well as the internalization and
endolysosomal turnover of neurotransmitter receptors beyond GABAergic ones (Figure 1). For instance,
autophagy induction following inhibition of either GSK3β or mTOR regulates dopamine and glutamate
release as well as the internalization of glutamate receptors [24,52–55]. The latter is associated with a
decrease in the amount of intracellular Ca2+ and reduced excitotoxicity [55–58], which are key events
implicated in seizure-induced neuronal damage (Figure 1).
Figure 1. The role of autophagy in seizure-related molecular mechanisms. By operating at the
level of gamma-aminobutyric acid (GABA), dopamine (DA) and glutamate systems autophagy are
critically implicated in the molecular mechanisms underlying epileptogenesis and seizure-induced
neuronal alterations. When a failure of autophagy occurs, elevated p62 hinders GABAA receptor
surface presentation, leading to decreased GABA signaling. At the same time, a failure of
autophagy occludes the degradation of glutamate receptors N-Methyl-D-Aspartate (NMDAR) and
A-Amino-3-Hydroxy-5-Methylisoxazole-4-Propionic Acid (AMPAR), fostering abnormal glutamate
signaling and Ca2+ influx. This eventually leads to imbalanced excitatory–inhibitory neurotransmission
underlying epileptogenesis. At the level of DA terminals, autophagy is seminal to blunt DA release by
degrading DA-filled synaptic vesicles. Autophagy failure leads to abnormal DA release and abnormal
stimulation of DA D1 receptors (D1DR), which in turn exacerbate autophagy suppression via mTOR
hyperactivation. This eventually leads to the accumulation of damaged cell substrates which synergize
with glutamate-related excitotoxicity to produce neuronal damage.
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2.2. Malformations of Cortical Development, TSC and FCD
Loss-of-function mutations in the two upstream mTOR regulators TSC and PTEN lead to
hyperactivation of mTOR, which correlates with a high incidence of epilepsy in both humans and
animal models [8–14,21,22,59–63]. The neurological syndromes associated with loss of PTEN or
TSC1/2, including TSC and FCD, are collectively known as mTORopathies. TSC is an autosomal
dominant disorder featuring severe neurological manifestations, including a high incidence (60%–90%)
of early-onset, intractable epilepsy [60,61]. Typical pathological changes include cortical tubers,
subependymal nodules, and subependymal giant cell astrocytoma (SEGA) [59–63]. Similar pathological
changes are seen in the cortical malformations that characterize patients with FCD, a localized
malformation of cortical development representing the commonest cause of severe childhood
epilepsy [60,61]. Aberrant mTOR hyperactivation through autophagy impairment is widely implicated
in epileptogenesis [12,13,21,22]. In fact, conditional deletion of TSC1 and PTEN in mice forebrain
neurons leads to severe seizures and increased mortality, which is associated with impaired autophagy
activity [21]. These findings are recapitulated in human TSC and FCD brain specimens [21,22]. In fact,
tubers and SEGA from TSC patients display a significant increase in phosphorylation of Ulk1 at Ser757
along with an increase of phosphorylated S6 and accumulation of the cargo autophagy protein p62.
As shown by immunohistological staining, p62 accumulation occurs in morphologically distinct cell
types, including enlarged, dysmorphic, giant ganglion-like cells in cortical tubers and spindle-shaped
astroglial-like cells in SEGA. Similarly, balloon cells in FCD specimens contain prominent lysosomes
due to a lack of fusion with autophagosomes along with an abnormal accumulation of p62. In both
TSC and FCD, autophagy defects and epilepsy-related neuronal alterations can be, in part, reversed
by in vitro inhibition of mTOR, suggesting that abnormal activation of mTOR may contribute to
epileptogenesis through autophagy suppression in FCD and TSC [21,22].
Indeed, ablation of ATG7, specifically in relatively mature neurons within the cortex and
hippocampus of mice, produces per se spontaneous recurrent seizures, which are even more severe
than those induced by the ablation of TSC1 and PTEN [21]. At the immunohistological level, autophagy
suppression following ATG7-KO is reminiscent of what is observed in human TSC and FCD brains.
In fact, there is a marked accumulation of p62 throughout the forebrain, with a pronounced increase in
cortical neurons and hippocampal CA1 and CA3 pyramidal cells, and within the dentate gyrus (DG).
Autophagy suppression correlates with a marked development of spontaneous seizures occurring
mostly around postnatal weeks 8–10, along with an abnormal electrographic activity and reduced animal
survival [21]. The present findings suggest that epileptogenesis is not restricted to a developmental
time point; rather, it seems to be a continuous process throughout the life course. This hypothesis is also
clinically relevant for those TSC patients who develop seizures during adolescence or adulthood [64].
Thus, targeting the mTOR/autophagy pathway could still be effective at a later point in life in TSC
patients or in those with a later onset of seizure manifestation.
2.3. Autism Spectrum Disorders
The autophagy machinery is key for both synapse formation and pruning during development [65,
66]. Autophagy suppression due to mTOR hyperactivation is implicated in aberrant synapse
formation and refinement in autism spectrum disorders (ASD), which are associated with epilepsy [67].
In detail, mTOR hyperactivation in mice leads to spine pruning deficits in cortical projection neurons,
indicating that autophagy is essential for synaptic pruning and that defects in autophagy contribute to
autism-spectrum-like phenotypes [68].
Defects in autophagy machinery have been associated with aberrant axonal homeostasis
underlying seizure-associated neurodevelopmental disorders. In detail, de novo pathogenic mutations
in the autophagy gene WDR45 (a mammalian homolog of yeast ATG18), which encodes a WD40
repeat-containing PtdIns(3)P binding protein, are detected in patients with developmental and epileptic
encephalopathies [19,20]. For instance, WDR45 mutations leading to impaired autophagy flux and
accumulation of aberrant autophagy structures are detected in static encephalopathy of childhood
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with neurodegeneration in adulthood [19]. WDR45 mutations in mice lead to cognitive impairment
and defective axonal homeostasis, due to the accumulation of p62 and ubiquitin-positive protein
aggregates which recapitulate some hallmarks of beta-propeller protein-associated neurodegeneration
(BPAN) featuring adolescent-onset dementia, dystonia, and seizures [69].
Autism-like behavior with increased seizure propensity is reported in female patients with a
heterozygous deficiency in the key autophagy gene Ambra1 [70]. Remarkably, Ambra1+/- mice which
possess impaired autophagy show increased pentylenetetrazole (PTZ)-induced seizure propensity and
a dysbalance of neuronal excitation-inhibition readout. The key role of autophagy in epileptogenesis
underlying ASD is recapitulated in experimental fragile X syndrome (FXS) featuring a loss of neuronal
fragile X mental retardation protein (FMRP) which is bound to mTOR overactivation and autophagy
suppression [71]. FMRP deficiency leads to increased neuronal excitability and susceptibility to an
epilepsy syndrome overlapping with benign focal epilepsy of childhood (benign rolandic epilepsy;
BFEC) [72]. In mice models of FXS, it was recently demonstrated that autophagy is key in synaptic
plasticity by degrading the synaptic scaffolding protein PSD-95, which is critical to spine morphology,
and the immediate early gene Arc, which is critical for CA1 synapses plasticity [71]. In FMRP-KO
neurons, mTOR hyperactivation and suppression of autophagy are bound to reduced degradation of
PSD-95 and Arc, leading to an overabundance of filopodial-like spines, exaggerated long-term
depression related to glutamate metabotropic receptors (mGluR-LTD), and impaired cognition.
Acute knockdown of Raptor, a binding partner of mTORC1, activates autophagy, thereby enabling
autophagy-dependent degradation of PSD-95 and Arc. This, in turn, corrects spine morphology,
as well as mGluR-LTD at CA1 synapses and cognition in FMR1-KO mice. While it is well established
that increased protein synthesis contributes to elevated PSD-95 and Arc, these findings document an
additional role for impaired protein degradation in neurodevelopmental disorders [71]. These findings
provide a potential mechanism by which down-regulated autophagy can lead to aberrant spine structure
and synaptic plasticity at CA1 synapses, which may be relevant for seizure-associated disorders.
2.4. Astrocytomas
Epilepsy often develops in patients with high-grade astrocytoma (glioma), and the two conditions
share common pathogenic mechanisms [73]. These include, for instance, altered expression of glutamate
transporters and increased concentrations of extracellular glutamate, which contribute to epileptic
discharge, tumor proliferation, and peripheral excitotoxicity. Again, hyperactivation of the mTOR
pathway and concomitant autophagy suppression is a hallmark in the development and progression
of high-grade astrocytoma [74]. In support of this overlap, antitumor therapy can contribute to
seizure control, and antiepileptic drugs might have beneficial effects on tumors. This is the case
of mTOR inhibitors and in particular Rapalogues. Discontinuation of Everolimus (prescribed for
growing subependymal giant cell astrocytomas) is associated with seizure relapse, and seizure control
is regained after reintroducing the drug [75]. Thus, clinical data support the potential of mTOR
inhibitors in treating epilepsy in brain tumors.
2.5. Lafora Disease
Lafora Disease (LD) is the most frequent form of a group of epilepsies named progressive
myoclonic epilepsies (PME). In fact, LD is an autosomal recessive disorder characterized by epileptic
seizures, progressive myoclonus, and neurodegeneration, which is associated with the massive
accumulation of polyglucosan inclusion bodies (Lafora bodies) [76]. LD is due to defects in either the
laforin protein phosphatase or the malin ubiquitin ligase. The occurrence of inclusion bodies within
different tissues indicates altered cell clearing pathways in LD. Accordingly, normal laforin is critical
to promote autophagy progression [77], while the laforin–malin complex promotes degradation of
intracellular misfolded proteins also by activating the UPS [78]. Thus, both laforin- and malin-KO
cells display mTOR-dependent autophagy defects and reduced UPS activity [78]. The interconnection
between LD and autophagy impairment has been proposed by several studies [79–81]. As shown
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in mice lacking laforin, autophagy impairment is considered as the primary trigger in LD [80,81].
This might be correlated with an early impairment of hippocampal and cortical GABAergic neurons,
which anticipates the appearance of LD [82,83]. Recently, the autophagy-related transcription factor
FoxO3a was identified as a possible cause for autophagy suppression in cellular and animal models
of LD. In detail, the expression levels of FoxO3a and its targets LC3II and ATG12 are reduced in
laforin-deficient cells and mice. Since FoxO3a exerts a negative control over mTOR, its loss could lead
to autophagy defects associated with laforin deficiency [84].
2.6. Antiphospholipid Syndrome and Systemic Lupus Erythematosus
Chronic seizures often result from autoimmunity. This is best exemplified by antiphospholipid
syndrome (APS) and SLE, prototypical autoimmune diseases that involve the CNS in most patients [85].
SLE is a prominent cause of seizures, which often represent an initial manifestation of the disease [86].
As recently addressed, mTOR pathway activation is a critical driver of inflammatory lineage
development in autoimmune diseases including SLE [16]. In T cells from both SLE patients and
animal models, oxidative stress along with a concomitant depletion of antioxidant factors occurs,
which leads to a redox-dependent activation of mTOR. In turn, oxidative stress and mitochondrial
dysfunction in T cells promote the release of highly diffusible inflammatory lipid hydroperoxides [87].
Oxidative stress is spread to other intracellular organelles and through the bloodstream, fostering
modification of self-antigen proteins, lipids, and DNA, and eventually, development of autoimmunity.
Thus, in autoimmune disorders such as SLE, oxidative stress may be key in bridging mTOR
activation and immunogenicity of phospholipid antigens [88]. In SLE, abnormal T cell activation is
associated with metabolic and organelle homeostasis, especially the mitochondrial, endosomal, and
autophagy compartments [89]. This is not surprising since mTOR-dependent autophagy governs
key metabolic cascades that dictate T- and B-cells’ differentiation, function, and activity [90,91].
Autophagy is also key in adaptive immunity, being implicated in the major histocompatibility class II
(MHC-II)-restricted presentation of exogenously derived antigens to CD4+ T cells [92,93]. Autophagy
also handles MHC-I internalization and degradation, thus influencing MHC-I stability at the plasma
membrane of antigen-presenting cells (APCs), and subsequent CD8+ T-cell responses [94,95]. In fact,
autophagy inhibition within APCs occludes the surface internalization of MHC-I molecules, leading
to autoimmunity due to increased endogenous antigen presentation and stimulation of autoreactive
T-cells [96]. This is intriguing since mTOR activation, and likely autophagy alterations, underlie
the generation of antiphospholipid antibodies (aPL), which are mediators of seizure in adults and
children alike [17,18]. Remarkably, aPLs from APS patients are able to gain access to the CNS following
injection in mice, suggesting that they may play a direct role in the pathogenesis of neurological
manifestations in APS/SLE [97]. Despite not being fully characterized, the mechanisms leading to
neurological manifestations may include aPL-induced micro- and macro-thrombosis, alterations of
brain–blood barrier and immune-mediated neuronal toxicity in the brain [98]. As far as it concerns
the pathogenesis of epilepsy, it has been shown that exogenously administered IgG–aPL from APS
patients induces depolarization of mouse brain synaptoneurosomes [99]. aPLs were recently shown to
reduce autophagolysosomal proteolysis in monocytes, suggesting that dysregulation of autophagy
may be bound to monocytes hyperactivation in APS/SLE [100]. Similarly, mTOR-dependent autophagy
impairment was documented within SLE monocytes following sustained inflammatory stimuli
such as IFNα. This, in turn, is associated with enhanced mitochondrial damage, oxidative stress
and accumulation of undigested mitochondrial DNA (mtDNA) which is released extracellularly to
trigger anti-DNA autoimmunity [101]. Accordingly, polymorphisms in the ATG5 gene are associated
with disease susceptibility in SLE patients, with the rs2245214 polymorphism being significantly
associated with a higher risk of producing anti-DNA autoantibodies [102]. In mice models, defects in
LC3-associated phagocytosis, a noncanonical form of autophagy, cause SLE-like phenomena including
increased serum levels of inflammatory cytokines and autoantibodies [103]. Contrariwise, the mTOR
blockade has remarkable therapeutic benefit in mice and patients with SLE [32,33,104]. In SLE patients,
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rapamycin treatment normalizes cytosolic and mitochondrial Ca2+ levels and T-cell-activation-induced
Ca2+ fluxing, which are known to contribute to the inflammatory process in SLE [33]. As thoroughly
reviewed elsewhere, rapamycin also limits the proliferation and activity of autoreactive T cells by
promoting regulatory T cell and tolerogenic dendritic cell expansion, and it blunts proinflammatory
IFN-α production by plasmacytoid dendritic cells and blunts T cell stimulation of autoreactive B
cells in SLE [7]. Thus, mTOR inhibitors, and potentially autophagy activators, may influence seizure
development by acting outside the CNS through modulation of proinflammatory linage development
(Figure 2) [88]. mTOR-dependent autophagy alterations may be also implicated in the generation of
self-antigens which reach the CNS to produce alterations of cortical excitability, though this remains to
be specifically demonstrated (Figure 2).
Figure 2. mTOR-dependent seizure development in autoimmune systemic disorders. Within peripheral
immune cells, mitochondrial alterations lead to chronic oxidative stress (production of reactive oxygen
species (ROS)) along with a concomitant depletion of antioxidant factors (gluthatione, GSH). This
promotes oxidation of self-antigen proteins, lipids, and DNA, along with calcium (Ca2+) influx and the
release of highly diffusible oxidative and inflammatory factors, which are spread to other intracellular
organelles and through the bloodstream. At the same time, redox imbalance induces mTOR activation
and autophagy impairment, eventually leading to impaired removal of oxidized self-antigens and
mitochondria, production of inflammatory cytokines by costimulatory dendritic cells, increased stability
of major histocompatibility molecules (MHC) on dendritic cells, subsequent activation of autoreactive
T cells and production of autoantibodies by B cells. Autoantibodies, activated immune cells, and
proinflammatory cytokines are spread through the bloodstream, and they reach the CNS where they
produce endothelial damage and disruption of the blood–brain barrier (BBB). Within the brain milieu,
these factors, coupled with mTOR hyperactivity and autophagy, impairment promote a chain of events
consisting of neuroinflammation through activation of glial cells, altered cortical excitability, and
eventually neuronal damage.
Int. J. Mol. Sci. 2020, 21, 1642 9 of 24
2.7. Experimental Models of Acquired Epilepsy
Common brain injuries, such as status epilepticus (SE), stroke/ischemia, and neurotrauma,
are associated with acquired epilepsy, which develops in three phases: (i) the injury (CNS insult),
(ii) epileptogenesis (latency), and (iii) the chronic epileptic (spontaneous recurrent seizure) phases [2].
Most experimental models are set up to mimic temporal lobe epilepsy (TLE), the most common
form of epilepsy comprising two-thirds of patients with intractable seizures. These models produce
seizures that originate from the hippocampus and/or limbic cortical areas, and they include lesions
such as excitotoxic SE, electrically induced seizure, and traumatic brain injury, as well as induction of
inflammatory processes by hyperthermia and viral inflammation, among others [11]. Two well-known
models consist of the systemic administration of chemoconvulsants like kainic acid (KA, an agonist
of glutamatergic non-NMDA receptors), or pilocarpine (PILO, an acetylcholine muscarinic receptor
agonist). In rodents, these models produce limbic seizures, which are secondarily generalized and can
be easily scored in terms of behavior (through specific behavioral scales), electroencephalographic
(EEG) features, and duration [12]. In these models, a neuropathological alteration reminiscent of
human TLE occurs, namely mesial temporal sclerosis or Ammon’s Horn Sclerosis [12,105]. It consists
of the loss of pyramidal cells of the CA areas CA1 and CA3–CA4, along with the loss of interneurons
of the hilus of the DG, and aberrant proliferation of mossy fibers originating from DG granule cells,
which is known as mossy fiber sprouting [106].
Other epilepsy models exist as well which bear interesting features for studying epileptogenesis.
For instance, pentylenetetrazole (PTZ) is a GABAa receptor antagonist used to induce seizures in
experimental settings through decreasing inhibitory GABA activity. PTZ’s effect is most prominent
in the cortex and hippocampus, and its acute administration is a valuable model of generalized
tonic-clonic and myoclonic seizures [107,108], while repetitive administrations of PTZ (kindling) are
needed to induce SE and pathological alterations [109,110]. Chemical kindling seizures triggered
by PTZ are assumed to mimic the pathogenesis of human epilepsy and are considered a model of
drug-resistant epilepsy [109,110]. In the following sections, we discuss the role of mTOR/autophagy in
various experimental models of acquired epilepsy.
2.7.1. Chemoconvulsive (Kainite and Pilocarpine) and Electroconvulsive Status Epilepticus
KA-induced seizures produce a biphasic activation of mTOR [111]. In detail, an increase in P-S6
expression occurs at 1 h after seizure onset, reaching a peak at 3-6 h and returning to baseline by
24 h in the hippocampus and neocortex of mice. After resolution of SE, a second increase in P-S6
occurs in the hippocampus starting at 3 days, peaking at 5–10 days, and persisting for several weeks
after KA injection. Remarkably, such a persistent increase correlates with the development of chronic
epileptogenesis [111]. Pretreatment with rapamycin through inhibition of mTOR abolishes both the
acute and chronic phases of KA-induced seizures, neuronal cell death, and mossy fiber sprouting. When
rapamycin is administrated after the termination of SE, it reverses only the chronic phase of mTOR
activation while reducing mossy fiber sprouting and epilepsy without any evident effects on neuronal
death [111]. Similar results on mossy fiber sprouting were obtained in a model of PILO-induced status
epilepticus [112]. Focal infusion of rapamycin for 1 or 2 months into the dorsal hippocampus after SE
reduces mossy fiber sprouting. These effects progressively disappear following rapamycin withdrawal.
Thus, mTOR inhibition, at least in PILO-induced SE, may not be sufficient per se to persistently prevent
the onset of epilepsy; rather, long-term rapamycin exposure may be mandatory to prevent seizure
onset. These findings are recapitulated under the term epileptostatic for describing the mechanisms
through which rapamycin may interfere with the effects of epileptogenic insults [11,14].
In murine models of KA-induced seizures, the deletion of mTOR from 44% of the astrocyte
population leads to a lower seizure frequency while ameliorating astrogliosis in the sclerotic
hippocampus compared with controls [113]. These effects are bound to mTOR-dependent increased
stability of the astroglial glutamate transporter 1 (Glt1) and subsequent enhanced extracellular
glutamate removal by astrocytes.
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A correlation between mTOR-dependent protection against blood–brain barrier disruption and
seizure severity was observed in a rat model of electrically induced SE through angular bundle
stimulation [114]. In detail, rats chronically administered with rapamycin starting 4 hours after
electrically induced SE are refractory to develop spontaneous seizure, and they are partially protected
from neuronal loss and mossy fiber sprouting. These beneficial effects correlate with reduced
blood–brain barrier leakage compared with controls, though the mechanism by which rapamycin
maintains the blood–brain barrier integrity remains to be elucidated [114].
Contrary to the consensual results on mTOR hyperactivation, the role of autophagy in SE
appears puzzling, yet as a double-edged sword. In hippocampal extracts from KA-treated mice, the
levels of phospho-mTOR increase from 6 to 16 h, while phospho-Akt increases at 16 h following
KA treatment [115]. Intriguingly, a significant increase in the amount of LC3-II is detected at 4–6 h
following KA, though such an effect is not paralleled by alterations in ATG5, ATG6, and ATG7 levels.
These data were interpreted as a transient induction of autophagy attempting to face excitotoxic cell
death in the mouse hippocampus [115]. In line with this, KA-induced seizures also cause an immediate,
though transient, vacuolization of astrocytes, which precedes astrogliosis [116]. These events are
prevented by pre- or post-treatment with rapamycin, indicating a transient induction followed by a
progressive impairment of autophagy flux which cannot cope with frank astrogliosis.
An upregulation of LC3-II has been similarly detected in the hippocampus of rats with
lithium-PILO-induced SE [117]. In order to exclude that the increase in LC3-II expression was due to
stagnant autophagosome accumulation or to a reduction in lysosomal activity, parallel evaluation of
the expression of LC3 and the lysosomal marker LAMP1 was monitored. At 24 h post-SE, LAMP1 was
highly expressed, and accumulated along with LC3-positive-dots within DG mossy fibers [117]. In line
with these findings, in a mice model of SE with electroconvulsive seizures occurring in the absence
of neuronal loss, increased levels of ATG5–ATG12 and LC3-II were detected in the hippocampus,
the dentate gyrus, and the CA [118]. Whether such an autophagy increase might contribute to
exacerbating SE, or whether it might occur as a compensatory attempt to survive the epileptic insult by
coping with synaptic and neuronal rearrangements, is still a matter of debate and ongoing investigation.
In support of the second hypothesis, chronic overactivation of glutamate receptors leads to
autophagy impairment due to the blockage of autophagy progression [119]. Indeed, despite producing
an increase in autophagy markers, excitotoxic glutamate produces a late-stage block of autophagy
in vivo in hippocampal neurons [120]. Consistently, excitotoxic neuronal cell death is worsened by
autophagy blockers while it is prevented by autophagy inducers [121–123].
Again, it has been documented that phospholipase D (PLD), which acts as an inhibitor of
mTOR/AMPK-autophagy [124,125], is implicated in KA-induced seizures [126]. In detail, PLD is a
downstream target of the GTPase Rheb, which is inhibited in response to AMPK via TSC [124]. In fact,
the inhibitory effects of PLD on AMPK activity are mediated by mTOR, and a reciprocal feedback
mechanism involving AMPK and mTOR is involved in PLD-mediated autophagy suppression [124].
PLD suppresses autophagy by modulating mTOR and AMPK-dependent phosphorylation of ULK1
and also by suppressing the interaction of Beclin-1 with vacuolar-sorting protein 34 (Vps34) [125].
Conversely, PLD inhibition enhances autophagy flux, indicating that PLD coordinates major players
of the autophagy pathway [125]. Remarkably, the levels of both PLD1 and PLD2 isoenzymes are
increased in the rat hippocampus after KA-induced seizures [126]. PLD1 immunoreactivity following
KA injection is preferentially increased within the CA3 and CA1 subregions, and this occurs mostly
within reactive astrocytes, likely in response to brain insults at the late stage when remodeling occurs.
Likewise, PLD2 expression in reactive astrocytes persists at 10 d after KA injection. On the other
hand, PLD2 increase within neurons peaks at 1 to 3 d and returns at baseline 10 d after seizure insult.
Intriguingly, aberrant neuronal expression of PLD2 is restricted mainly to the infrapyramidal blade
of the DG. This is in line with studies demonstrating that after KA-induced seizures, the sprouted
axon collaterals from granule cells in the infrapyramidal blade cross the hilus and project into the
supragranular layer of suprapyramidal blade, but not vice versa [127]. Thus, PLD2 expression in the
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infrapyramidal blade of the DG may play a role in the characterization of the spatial distribution of the
sprouted mossy fiber pathways after epileptic seizures [126]. Since PLD overexpression is bound to
autophagy suppression via mTOR upregulation, it would be worth investigating whether a causal
relationship exists between PLD and autophagy alterations in seizure-induced alterations within the
infrapyramidal blade of the DG.
In murine models of PILO-induced SE, mTOR-dependent autophagy was recently associated with
the beneficial effects of several phytochemical compounds such as curcumin (C. Longa), Ginkgo biloba L.
(Ginkgoaceae), and Aucubin (Eucommia ulmoides Oliv.). Treatment with Ginkgo biloba reduces seizure
severity score, and it improves spatial cognitive functions and recognition memory while protecting
against neuronal damage and mossy fiber sprouting in the DG and CA. These effects occur along with
a reduction of hippocampal mTOR and its downstream ribosomal S6 and pS6 protein levels [128].
Likewise, in models of PILO-induced status epilepticus, either aucubin or curcumin protects from
post-SE cell death within DG, Hilus, CA1, and CA3 hippocampal regions through autophagy activation
and inhibition of necroptosis [29,30].
In recent years, lithium, a classic mood stabilizer and autophagy inducer, was shown to
produce neuroprotective effects in many neurological diseases, including epilepsy. The effects
of systematically administered lithium on PILO-induced seizure activity, susceptibility, and severity
are dose-dependent [31]. In detail, while high-dose lithium (40 mg/kg) increases the susceptibility and
severity of PILO-induced seizures, low-dose lithium (10 mg/kg) administered to PILO-treated rats
markedly decreases the proportion of Racine stage 4–5 seizures, it extends latency until seizure onset
and significantly reduces the frequency of lower-class seizures [31]. Despite the autophagy-related
effects of lithium not being examined, these findings provide a framework for further investigating
the implication of autophagy in the electrophysiological mechanisms of excitatory and inhibitory
imbalances within neural circuits which regulate seizure activity.
2.7.2. Pentylenetetrazole (PTZ)-Induced Seizures
Contrary to models of chronic epilepsy such KA, which exhibit biphasic mTOR pathway activation,
PTZ seizures were shown to produce only acute mTOR activation, while administration of PI3K
inhibitors prevents PTZ acute epileptogenesis [108]. In PTZ-treated larval, juvenile, and adult zebrafish,
rapamycin pretreatment slows down the progression of seizures by prolonging the latency to reach the
tonic–clonic stage (stage III) [129]. Similar results are reported in rat models of PTZ-induced kindling,
which feature mTOR hyperactivation [130]. In detail, a massive increase in phospho-mTOR and its
downstream targets occurs in the hippocampi of PTZ-treated rats. This is attenuated by pretreatment
with adenosine, acting as an alternative, endogenous anticonvulsant [130]. Adenosine-induced
suppression of mTOR and S6 phosphorylation can be reversed by the application of compound C,
an inhibitor of AMP-activated protein kinase (AMPK), which acts as an upstream suppressor of the
mTOR pathway and autophagy activator. This suggests that autophagy impairment due to mTOR
hyperactivation and AMPK downregulation may be implicated in PTZ-induced kindling [130].
The role of autophagy in PTZ-induced SE was recently confirmed by a study evaluating the
potential therapeutic effects of endothelial progenitor cells (EPCs) in sustained seizures [110]. EPCs may
confer therapeutic effects against epilepsy and its associated behavioral and biochemical abnormalities,
at least in part, via the upregulation of autophagy. In detail, intravenously administered EPCs home
into the hippocampus, where they mitigate PTZ-induced behavioral abnormalities, neurological
damage, and histopathological alterations, as well as perturbations in neurotransmitter activity. These
effects correlate with an increase in LC3, Beclin-1, and ATG7 levels, and they are reproduced by the
administration of the antiepileptic drug valproic acid [110], which is known to induce autophagy
through mTOR/Akt inhibition [131].
Autophagy activation is also detected following ibuprofen administration in PTZ-treated rats,
which is associated with reduced seizure number, duration, and severity, along with decreased
astrogliosis and astrocyte proliferation [132]. Likewise, autophagy is implicated in the beneficial effects
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of the ketogenic diet (KD) in PTZ-kindled rats [133]. KD alleviates seizure severity while decreasing
the number of apoptotic cells and the number of damaged mitochondria in the hippocampi of kindled
rats. These effects correlate with autophagy activation as evidenced by an increase of hippocampal
Beclin-1, ATG5, and LC3-II/ LC3-I ratio along with a decrease of the autophagy substrate p62 compared
with PTZ-kindled rats which are fed with normal diet [133]. Remarkably, these effects are abolished
by pretreatment with the autophagy inhibitor 3-MA, while rapamycin pretreatment protects from
neuronal cell death in the hippocampus despite not affecting seizure severity.
In a mice model of PTZ-induced seizures, protective autophagy-related effects were also reported
for sitagliptin, a selective inhibitor of dipeptidyl peptidase (DPP)-4 that is commonly used in the
treatment of type 2 diabetes [134]. Sitagliptin improves neurochemical alterations and protects against
PTZ-induced neurotoxicity by i) enhancing hippocampal GABA activity and reducing glutamate
activity; ii) producing anti-peroxynitrite, antioxidant, and anti-inflammatory effects; and iii) reducing
caspase-3-related apoptosis while enhancing autophagy. In this context, the increase in autophagy
activity is paralleled by Nrf2 activation, which is implicated in mitophagy and mitochondriogenesis
beyond antioxidant defense [134]. The antiepileptic, protective, and autophagy-inducing effects of
sitagliptin are enhanced upon coadministration with pregabalin, suggesting that autophagy holds center
stage in the biochemical mechanisms underlying the antiepileptogenic potential of these compounds.
Similar to what is reported for PILO, the autophagy inducer lithium produces anticonvulsive
and neuroprotective effects in murine models of PTZ-induced seizures [135]. While acute lithium
administration (30 mg/kg) enhances the proconvulsive properties of PTZ, chronic pretreatment with
lithium (7 days, 10 mg/kg) significantly increases the seizure threshold. At the same time, lithium
confers neuroprotection in primary cerebellar cultured neurons by counteracting glutamate-induced
excitotoxicity. In fact, both anti-epileptogenic and neuroprotective effects of lithium are reversed by the
coadministration of an NMDA receptor antagonist [135]. It is remarkable that similar to the protective
effects of mTOR inhibitors against the neurotoxic convulsant quinolinic acid [58], lithium protects
against glutamate-induced neurotoxicity, and such an effect is associated with autophagy activation,
mostly related to GSK3β inhibition [119–123]. Besides promoting neuronal survival following
glutamate-induced injury, inhibition of either mTORC1 or GSK3β similarly prevents NMDA-induced
decrease in spontaneous excitatory postsynaptic currents [55]. This suggests that the plastic effects
of excitatory–inhibitory transmission dysbalance involve a common mechanism which requires the
permissive activity of mTORC1 and GSK3β, likely converging in a failure of the autophagy pathway.
This is in line with the abovementioned evidence indicating that a crosstalk occurs between GSK3β
and mTOR during brain development [45]. TSC2 is key in mediating such a cross-talk since GSK3
directly binds to and phosphorylates TSC2 in neural progenitors [45]. This phenomenon, which may
disclose novel autophagy-related regulatory pathways in epilepsy, remains poorly characterized and
deserves further investigation.
2.7.3. Ischemic/Hemorragic Stroke and Brain Trauma
Pre-ischemic hyperglycemia increases the occurrence of post-ischemic seizures both in clinical
and experimental settings [136]. The development of post-ischemic seizures in hyperglycemic animals
is associated with activation of mTOR and ERK1/2 pathways. Rapamycin treatment inhibits the
post-ischemic generalized tonic–clonic seizures while protecting from neuronal death in hyperglycemic
ischemic rats through inhibition of mTOR and ERK pathways [136].
Stroke is also implicated in the etiology of seizures development. In rat models of global cerebral
ischemia (GCI), during the first and the second days following GCI, convulsive seizures frequently occur,
which are accompanied by seizure discharge shown by the EEG [137]. Convulsive seizures occur along
with an increased expression of phospho-mTOR and GLUT-1 in the cerebral cortex and hippocampus, as
evidenced by immunohistochemistry and western blot analyses. Mild hypothermia and/or rapamycin
treatment alleviates GCI-induced seizures by reducing the number of epileptic attacks, seizure severity
scores, and seizure discharges [137]. This goes along with a reduction of phosphor-mTOR and its
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downstream effector p70S6 in neurons. Thus, mTOR is involved in stroke-induced seizures and
targeting mTOR hyperactivation through rapamycin, and mild hypothermia produces antiseizure
effects [137].
In a rat model of FeCl2-induced post-traumatic epilepsy (PTE), p-mTOR and p-P70S6K are
increased significantly in the hippocampus and perilesional cortex [138]. Rapamycin administration
decreases mTOR activity markers while reducing the frequency and number of behavioral seizures
and epileptic brain injury [138].
The role of autophagy in cerebral ischemia, stroke, and brain trauma is still ambiguous, with
numerous studies describing autophagy either as mediating neuronal death or protection [139–141].
To date, there is a paucity of studies investigating the role of autophagy specifically in epileptogenesis
associated with these disorders. An exception is cerebral cavernous malformation (CCM), a major
cerebrovascular disease characterized by enlarged and leaky capillaries that predispose one to seizures,
focal neurological deficits, and fatal intracerebral hemorrhages [142]. Causative loss-of-function
mutations associated with both sporadic and familial forms have been identified in three genes, namely
KRIT1 (CCM1), CCM2 (MGC4607), and PDCD10 (CCM3). Recently, it was demonstrated that the
ablation of the KRIT1 gene strongly suppresses autophagy, leading to the aberrant accumulation of
the autophagy adaptor p62, defective quality control systems, and increased intracellular stress [142].
KRIT1 loss-of-function suppresses autophagy through activation of the mTOR-ULK1 pathway, while
treatment with mTOR inhibitors rescues some of the molecular and cellular phenotypes associated
with CCM [142]. Insufficient autophagy is also evident in CCM2-silenced human endothelial cells,
in cells and tissues from endothelial-specific CCM3-KO mice, as well as in human CCM lesions [142].
Furthermore, defective autophagy is highly correlated to endothelial-to-mesenchymal transition,
a crucial event that contributes to CCM progression.
2.7.4. DA-Dependent Kindled Seizures
Repeated systemic administration of a type 1 DA receptor (D1DR) agonist (SKF81297) was
shown to induce kindled seizures in mice [27]. Remarkably, this occurs along with hyperactivation
of the mTOR signaling in the hippocampus. These effects are associated with disrupted long-term
potentiation (LTP) in the DG and altered recognition memories. Conversely, rapamycin administration
delays the development of SKF81297-induced kindled seizures, and it rescues LTP in the DG and
object recognition [27]. This suggests that abnormal stimulation of DA D1 receptors (D1DRs) is
sufficient to induce generalized seizures, leading to the overactivation of mTOR signaling, disrupted
hippocampal plasticity, and impaired long-term recognition memories. Likewise, in experimental
hepatic encephalopathy, abnormal stimulation of D1DRs alters synaptogenesis by producing a reduction
of GABAA-induced currents due to the loss of interaction of GABAA receptors with AKT, which is placed
upstream of mTOR-dependent autophagy [143]. It is remarkable that mTOR-dependent autophagy
is key to blunt abnormal electrically evoked DA release through the degradation of DA-containing
synaptic vesicles [52]. Thus, autophagy is key to prevent both abnormal stimulation of D1DRs and
dysfunction of GABAA receptors, which indirectly suggests that autophagy induction may be key to
regulate cortical excitability through modulation of DA–GABA interactions. These findings are also key
in the context of epileptic seizures which sporadically occur following administration/intake of strong
DA-releasing abused drugs/psychostimulants such as amphetamines. In fact, amphetamines produce
an abnormal DA release featuring peaks and drops of extracellular concentration, which in turn lead
to abnormal pulsatile stimulation of D1DRs in the brain [28,144]. It is remarkable that abnormal
stimulation of D1DRs, as it occurs following amphetamine administration, leads to noncanonical
intracellular pathways, which produce mTOR hyperactivation and autophagy suppression [145,146].
These, in turn, may produce maladaptive plastic changes including altered cortical excitability and
abnormal NMDA and AMPA receptor stimulation up to glutamate-induced excitotoxicity [144].
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3. A Glance at mTOR-Related UPS Alterations in Epilepsy
Recently, increasing evidence indicates a functional cross-talk between UPS and autophagy,
which occurs at both biochemical and morphological levels [28,38–49]. This is largely due to the
mTOR pathway, which modulates both UPS- and autophagy-dependent protein degradation [30].
This is not surprising since autophagy and UPS share most of their substrates and functions, and
they operate coordinately in neurons and glia to modulate oxidative/inflammatory stress response,
neurotransmission, and synaptic plasticity [28]. In fact, the inhibition of either UPS or autophagy in
experimental models produces marked alterations in neurotransmitter activity, synaptic plasticity, and
neurodegeneration [52,147–149]. mTOR-related UPS dysfunctions beyond autophagy alterations are
now emerging in the field of epilepsy as well.
The coordinated turnover of synaptic membrane proteins via the UPS/autophagy–endolysosomal
pathway is essential for synaptic function. For instance, hypomorphic mutations in the ubiquitin
adaptor protein PLAA cause an infantile-lethal neurological syndrome with seizures in both humans
and mice [150]. Due to impaired degradation of ubiquitinated substrates, PlAA mutant neurons
accumulate K63-polyubiquitylated proteins and synaptic membrane proteins, disrupting synaptic
vesicle recycling, neurotransmission, and excitatory–inhibitory balance.
A downregulation of ubiquitin carboxyl-terminal hydrolase isozyme L1 (UCHL1) was recently
detected in murine models of SE induced by intra-amygdala KA injection [151]. UCHL1 inhibition
prior to SE decreases hippocampal ubiquitin, and it disrupts UPS function and the turnover of PSD-45;
moreover, it prolongs SE-induced seizures, and it attenuates the EEG response to anticonvulsant
lorazepam while exacerbating seizure-induced cell death. Remarkably, rapamycin administration
can reverse these effects by increasing UCHL1 expression in vivo. Thus, post-transcriptional loss
of UCHL1 following SE is deleterious to neuronal survival and may contribute to epileptogenesis
and epilepsy-induced brain damage, while mTOR inhibition can restore these alterations by rescuing
UPS beyond autophagy [152]. Inhibition of the UPS also exacerbates epileptogenesis in experimental
mesial TLE, causing early and frequent spontaneous seizures, neuron loss and aberrant mossy fiber
sprouting [152]. The UPS participates in the pathogenesis of mesial TLE through a mechanism that
involves the upregulation of Nedd4-2, a critical E3 ligase linked with ion channels and synaptic vesicle
recycling. In fact, inhibition of ubiquitin enhances the activation of Nedd4-2, which in turn switches the
α subunit epithelial sodium channel (α-ENaC) downstream, thus contributing to epileptogenesis [152].
The core machinery of the UPS, the 26S proteasome, is composed of β catalytic subunits existing
as either constitutive or inducible isoforms. During inflammation or oxidative stress, the constitutive
subunits of the P26S are replaced by their inducible counterparts, leading to the formation of the
immunoproteasome, which is endowed with pathophysiological functions related to immunity and
inflammation [35]. mTOR hyperactivation has been linked with downregulation of constitutive
proteasome subunits and subsequent induction of immunoproteasome. In the healthy human brain,
the expression of the catalytic inducible β5 (β5i) subunit of the immunoproteasome is almost absent,
while it is markedly enhanced in epileptogenic foci from patients with pharmaco-resistant seizures [36].
The induction of β5i immuno-subunit in neurons and glia occurs even in experimental epilepsy, and
its selective pharmacological inhibition significantly prevents, or delays, 4-aminopyridine-induced
seizure-like events in acute rat hippocampal/entorhinal cortex slices [36]. Likewise, increased expression
of (immuno)proteasome subunits (β1i, β5i) is detected in the post-SE rat model of TLE, in both neurons
and astrocytes within the hippocampus and piriform cortex. Rapamycin-treatment in post-SE rats
reduces (immuno)proteasome expression and the number of spontaneous seizures compared to
vehicle-treated rats. (Immuno)proteasome expression is also increased in neurons and astrocytes
within the human hippocampus after SE and in patients with drug-resistant TLE as well as TSC and
FCD [37,122]. In vitro studies using cultured human astrocytes showed that interleukin (IL)-1β-induced
(immuno)proteasome gene expression could be attenuated by rapamycin, supporting a role for altered
mTOR-dependent cell-clearing systems as a potential target in epileptogenesis [37,153].
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4. Conclusions
In the last decades, alterations of autophagy and UPS started to apply to the field of
epileptology besides neurodegenerative disorders. In the present review, increasing evidence was
presented indicating a link among both genetic and acquired forms of epilepsy with alterations in
mTOR-dependent cell-clearing systems. Despite wide evidence suggesting a failure of autophagy in
epileptogenesis and epilepsy-induced neuronal alterations, some controversies still exist which tone
down viewpoints linking autophagy failure with most of the epilepsy-related mTOR alterations.
In keeping with this, the effects of rapamycin, which is employed as a gold-standard mTOR
inhibitor and autophagy inducer, vary according to the dosing, timing, and experimental contexts [154].
Different doses of rapamycin are needed to suppress the phosphorylation of different mTOR substrates,
and differential sensitivity of the two mTOR complexes mTORC1 and mTORC2 to rapamycin
occurs [154]. The intriguing properties of rapamycin dosage are also bound to rapamycin’s competition
with phosphatidic acid (PA) for mTOR. Since PA is a central metabolite of membrane lipid biosynthesis
and the product of the PLD, which is increased in epilepsy, confounding outcomes cannot be ruled out.
Besides these considerations, potential side effects of mTOR inhibitors need to be taken into account.
Minimizing drug dosage to reduce side effects while maintaining therapeutic efficacy represents
indeed a major goal. Thus, mTOR inhibitor treatment is aimed at restoring mTOR to control levels
rather than completely shutting down its activity [155]. Extrapolating the absolute dosing and serum
levels from mice to humans is challenging, though in TSC mice models, moderate doses of rapamycin
(3 mg/kg/d) were shown to lower P-S6 at levels comparable with controls, while high doses (10 mg/kg/d)
completely inhibit P-S6 expression [155]. Another approach to reducing drug exposure and side
effects is intermittent dosing or drug holidays. Rapamycin treatment (3 mg/kg) with drug holidays of
24 days was shown to almost completely prevent epilepsy in TSC mice models [155]. Remarkably,
the antiepileptogenic effects of intermittent rapamycin dosing outlast the duration of mTOR inhibition,
indicating that the pharmacodynamic actions of mTOR inhibition persist beyond pharmacokinetic
properties [155]. Another issue that deserves further attention is that the vast majority of studies
employ LC3 quantification as a gold-standard assay for monitoring the autophagy status, which may
have considerable methodological limitations. This is magnified with immunofluorescent microscopy,
which can yield false-positive results due to the misdetection of LC3 puncta corresponding to cytosolic
rather than authentic autophagy-related structures [156]. In fact, endogenous LC3-positive puncta
are evident and become even larger in cells where autophagy is inhibited, questioning the reliability
of LC3-immunofluorescence in cells and tissues with compromised autophagy [156]. In line with
this, immune-gold-based electron microscopy remains seminal for detecting the ultrastructural LC3
compartmentalization within autophagy vacuoles, which is disrupted, for instance, by amphetamine
administration [40]. In fact, despite being LC3-increased following amphetamine intoxication, it loses
its polarization within autophagy-related structures [40]. Combining different techniques in order to
reliably investigate the autophagy status needs to be applied to the field of epilepsy as well. Another
issue which deserves to be investigated is the concomitant assessment of the contribution of each
cell-clearing pathway considering the novel scenario where autophagy and UPS represent a unified
mTOR-dependent cell-clearing apparatus. Overall, the findings discussed here encourage further
studies aimed at investigating the therapeutic potential of mTOR inhibitors and autophagy inducers in
seizure-related disorders.
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Abbreviations
FCD Focal Cortical Dysplasia
FMRP Fragile X Mental Retardation Protein
BFEC Benign Focal Epilepsy of Childhood
LTD Long-Term Depression
PME Progressive Myoclonic Epilepsy
FXS Fragile X Syndrome
GABARAP γ-Aminobutyric-Acid-Receptor-Associated Proteins





AMPK Amp-Activated Protein Kinase
EPCs Endothelial Progenitor Cells
KD Ketogenic Diet
DPP Dipeptidyl Peptidase




CCM Cerebral Cavernous Malformation
D1DR type 1 dopamine Receptor
LTP Long-Term Potentiation
AMPA A-Amino-3-Hydroxy-5-Methylisoxazole-4-Propionic Acid
UCHL1 Ubiquitin Carboxyl-Terminal Hydrolase Isozyme L1
α-ENaC α Subunit Epithelial Sodium Channel
DA Dopamine
LD Lafora Disease
mTOR Mammalian Target Of Rapamycin
PTEN Phosphatase And Tensin Homolog
PTZ Pentylenetetrazole
SEGA Subependymal Giant Cell Astrocytoma
CA Cornus Ammonis
DG Dentate Gyrus
ASD Autism Spectrum Disorders
BPAN Beta-Propeller Protein-Associated Neurodegeneration
TLE Temporal Lobe Epilepsy
TSC Tuberous Sclerosis Complex
UPS Ubiquitin-Proteasome System
SLE Systemic Lupus Erythematosus
APS Antiphospholipid Syndrome
MHC-II Major Histocompatibility Class-II





CNS Central Nervous System
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